Crossmark

Cost-effectiveness analysis of first line pembrolizumab monotherapy for high programmed cell death ligand 1 expressed, advanced non-small cell lung cancer in Japan

Crossref DOI link: https://doi.org/10.1007/s11096-024-01826-7

Published Online: 2024-11-20

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tomura, Kazuki https://orcid.org/0009-0000-2318-2706
Sakamaki, Hiroyuki

Nawata, Shuichi https://orcid.org/0000-0002-2193-9899
Ishida, Hiroo

Tanaka, Katsumi

Kogo, Mari https://orcid.org/0000-0001-7553-0872
License Information

Text and Data Mining valid from 2024-11-20

Version of Record valid from 2024-11-20
More Information

Article History

Received: 15 April 2024

Accepted: 18 October 2024

First Online: 20 November 2024

Conflicts of interest

: The authors have no conflicts of interest to declare.

Document is current

Any future updates will be listed below